Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Tuesday 23 April 2024 8:58 am  |  Updated:  Tuesday 23 April 2024 9:07 am

This may hurt: English High Court set for Moderna and Pfizer/BioNTech Covid battle starting today

By: Maria Ward-Brennan

Professional Services Editor

Add as a preferred source on Google
This may hurt: London High Court set for Modern and Pfizer/BioNTech covid battle
This may hurt: London High Court set for Modern and Pfizer/BioNTech covid battle. Photo credit Mufid Majnun

The English part of a global dispute billion dollar legal case involving big pharma giants Moderna, Pfizer and BioNTech over Covid patents, kicks off today.

Back in 2020 when Covid was spreading around the world, US pharma giant Modern’s mRNA vaccine was approved and issued for emergency use throughout the US.

The company made headline news after it said it wouldn’t enforce its patents related to Covid-19 vaccines during the pandemic, in an effort to not deter other companies and researchers from making similar vaccines. It later changed that position, limiting it to vaccines manufactured for low and middle-income countries.

The Massachusetts-based pharma company issued a lawsuit against US Pfizer and German BioNTech over allegedly breaching its patents. Commenting at the time, Moderna said it believed that Pfizer and BioNTech’s Covid vaccine infringed patents Moderna filed between 2010 and 2016 covering its mRNA technology.

Moderna claim suggests that it doesn’t want to remove Pfizer’s and BioNTech’s vaccines from the market, but instead, it wants compensation and damages.

This comes after the American company made more than $6bn (£5.7bn) in revenue during the pandemic. The company saw its turnover shoot up to $6.1bn (£7.6bn) for the Q1 of 2022, compared to $1.9bn (£1.5bn) for the same period in 2021.

Both Pfizer and BioNTech fired back and launched a counterclaim against Moderna claiming its patents are invalid and should be revoked.

The lawsuit has also been filed in the US, Germany and the Netherlands. Earlier this month, Pfizer won a pause on the litigation in the Massachusetts Federal Court, as the parties await a decision from the US Patent Office.

While the US is on hold, England is going full stream ahead. The trial kicks off on Tuesday and is set to last under four weeks at the Chancery Division of the High Court in London.

The hearing will be split into two parts, first will be the technical part which will look at the patents, while the second part will be looking at Moderna’s 2020 pledge.

The trial is in front of Mr Justice Meade at the Rolls Building. US giant Moderna has enlisted a team from magic circle law firm Freshfields, while, Pfizer has called on Taylor Wessing and BioNTech has instructed Powell Gilbert for their defence (and counterclaim).

For more on law on City PM

Read more

Regulator wins decade-long pricing tussle with Pfizer

Hikma reported a jump in profit for 2024

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Legal
  • Business

People & Organisations

  • covid
  • High Court
  • Law
  • Medical
  • Patents
  • Pharma
  • Vaccine

Related Topics

  • Covid

Trending Articles

  • Reeves’ new tax charge on cash ISAs faces fierce industry backlash

  • Revealed: Secret Treasury plan to tax State Pension before it is paid out

  • Burnham’s new chief of staff ran City firm advising Thames Water and rival Heathrow bidder

  • As it happened: Stocks recover after markets rocked by tech-sell off; US claims ‘good foundations’ of Iran deal

  • As it happened: FTSE 100 scrapes into green after Segro’s surge; Oil at pre-war levels after Trump snaps at industry

More from City PM

  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • Podcast: Palantir to sue Sadiq Khan, GSK’s $10bn mega-deal, and could the World Cup rescue pubs?

    Podcast
    City PM Business As Usual Podcast
  • The world runs on English law – let’s make the most of it

    Opinion
    The SRA has criticised law firms that handle high-volume consumer claims for poor practices
  • LivaNova Appoints Anne Liddy as Chief Legal Officer

    Business Wire
  • Matalan kicks off turnaround under new boss as retailer slashes jobs

    Retail
    Henrik Nordvall addressing a conference, wearing a suit, with a presentation screen in the background, engaging audience.
  • Lex Greensill banned as company director for nine years after multi-billion-pound collapse

    Business
    Lex Greensill speaking at a business conference, wearing a suit and tie, gesturing with his hand while discussing financia...
  • Has Fifa quietly made mandatory release clauses the future of football transfers?

    Sport Business
    Getty Images logo on a digital screen, representing media and stock photography in a business and news context.
  • GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn

    Pharma
    GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM. All rights reserved.
About · Contact · Terms · Privacy